Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Paclitaxel and ddAC in HR-Poor/HER2-Negative Breast Cancer
NCT00861705Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and carboplatin in breast cancer (4 arms), sponsored by National Cancer Institute. Primary endpoint: Pathologic Complete Response in the Breast up to 28 weeks. Started Jul 2009; status: completed.
02
Drugs
bevacizumabcarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00861705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861705.